TBIO elects its Board and reseats Wu Chung-hsiun as Chairman
2022-11-08
Taiwan BIO elects its Board and reseats Wu Chung-hsiun as Chairman
During its annual general meeting held October 27, The Taiwan Bio-Industry Organization (Taiwan BIO) elected its seventeenth board of directors and supervisors and reelected its current chair Wu Chung-Hsiun, CEO of the Development Center for Biotechnology (DCB) as Taiwan BIO Chairman. Election for Vice Chairman was also held, with the role to be shared by Jo Shen, Partner, Vivo Capital Ventures; and Audrey Tseng, Honorary Deputy Chairman, PwC.
In addition, six highly-regarded members of Taiwan’s biomedical community were elected as Supervisors to the Board of Taiwan BIO, including Bobby Sheng, Chairman and CEO of Bora Pharmaceuticals; Chen Pei-Jiun, Chairman and CEO of Mycenax Biotech; Daniel Cheng, President, San Fu Biotechnology; Jasmine Yu, Accountant, PwC; Susan Lu, President and CEO of ScinoPharm Taiwan; and Lee I-lin, Vice Chairman, Phytohealth.
Taiwan BIO was established in 1989, with 145 companies as corporate members from research institutes, investment firms, academia and government entities across the country, with the current board including notable leaders from across this spectrum.
Re-elected Chairman Wu Chung-Hsiun in his acceptance speech noted that the four major tasks of the association include promoting international engagement; building communication links between the government and industry; cultivating talent; and helping grow and encourage excellence both of companies and R&D in the biomedical industry space. Additional responsibilities include organizing and hosting the annual BIO Asia–Taiwan International Conference and Exhibition; participating in international biotechnology gatherings; holding seminars on how to contract with the government; holding professional training through its Biotech Academy, and organizing and hosting the annual Taiwan BIO Industry Awards.
Wu also pointed out that under the guidance of Chen Chien-Jen, Chief Consultant and former Vice President of Taiwan, Taiwan BIO has set up a number of industry, membership, and activity committees in agricultural biotechnology, biotechnology services, entrepreneurial integration, industry regulations, medtech, biosimilars, and international cooperation. By utilizing the knowledge and experience of the board, Wu expressed his hope that Taiwan BIO would be the platform to help bring together the resources of all stakeholders to better promote the development of the biomedical industry in Taiwan.
The other two Executive Directors appointed during the seventeenth session were Liu Lee-Cheng, Chairman, EirGenix; and Sytwu Huey-Kang, Vice President, National Health Research Institutes (NHRI). The Executive Supervisor position was assumed by Howard Lee, Chairman, Taho Pharmaceuticals. Former Taiwan BIO Chairman Johnsee Lee was re-appointed as Honorary Chairman.
During its annual general meeting held October 27, The Taiwan Bio-Industry Organization (Taiwan BIO) elected its seventeenth board of directors and supervisors and reelected its current chair Wu Chung-Hsiun, CEO of the Development Center for Biotechnology (DCB) as Taiwan BIO Chairman. Election for Vice Chairman was also held, with the role to be shared by Jo Shen, Partner, Vivo Capital Ventures; and Audrey Tseng, Honorary Deputy Chairman, PwC.
In addition, six highly-regarded members of Taiwan’s biomedical community were elected as Supervisors to the Board of Taiwan BIO, including Bobby Sheng, Chairman and CEO of Bora Pharmaceuticals; Chen Pei-Jiun, Chairman and CEO of Mycenax Biotech; Daniel Cheng, President, San Fu Biotechnology; Jasmine Yu, Accountant, PwC; Susan Lu, President and CEO of ScinoPharm Taiwan; and Lee I-lin, Vice Chairman, Phytohealth.
Taiwan BIO was established in 1989, with 145 companies as corporate members from research institutes, investment firms, academia and government entities across the country, with the current board including notable leaders from across this spectrum.
Re-elected Chairman Wu Chung-Hsiun in his acceptance speech noted that the four major tasks of the association include promoting international engagement; building communication links between the government and industry; cultivating talent; and helping grow and encourage excellence both of companies and R&D in the biomedical industry space. Additional responsibilities include organizing and hosting the annual BIO Asia–Taiwan International Conference and Exhibition; participating in international biotechnology gatherings; holding seminars on how to contract with the government; holding professional training through its Biotech Academy, and organizing and hosting the annual Taiwan BIO Industry Awards.
Wu also pointed out that under the guidance of Chen Chien-Jen, Chief Consultant and former Vice President of Taiwan, Taiwan BIO has set up a number of industry, membership, and activity committees in agricultural biotechnology, biotechnology services, entrepreneurial integration, industry regulations, medtech, biosimilars, and international cooperation. By utilizing the knowledge and experience of the board, Wu expressed his hope that Taiwan BIO would be the platform to help bring together the resources of all stakeholders to better promote the development of the biomedical industry in Taiwan.
The other two Executive Directors appointed during the seventeenth session were Liu Lee-Cheng, Chairman, EirGenix; and Sytwu Huey-Kang, Vice President, National Health Research Institutes (NHRI). The Executive Supervisor position was assumed by Howard Lee, Chairman, Taho Pharmaceuticals. Former Taiwan BIO Chairman Johnsee Lee was re-appointed as Honorary Chairman.